Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients (Q39381633)

11 September 2017

title

Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients (English)

1 reference

11 September 2017

0 references

prevention of HIV/AIDS

0 references

1 reference

1 reference

cryptococcal meningitis

1 reference

V J Quagliarello

1

1 reference

11 September 2017

C Viscoli

series ordinal

2

1 reference

11 September 2017

R I Horwitz

series ordinal

3

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 March 1995

1 reference

11 September 2017

1 reference

11 September 2017

volume

345

1 reference

11 September 2017

issue

8949

1 reference

11 September 2017

page(s)

548-552

1 reference

Cryptococcal meningitis and AIDS.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Fluconazole, a new antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

The case-control study. A practical review for the clinician

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Does prophylaxis prevent postdental infective endocarditis? A controlled evaluation of protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

Choosing cases and controls: the clinical epidemiology of "clinical investigation".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990465-4

7 January 2021

10.1016/S0140-6736(95)90465-4

Identifiers

DOI

1 reference

11 September 2017

1 reference